文献速递肝胆胰外科

微创保留实质胰腺切除术后内分泌与外分泌功能不全的发生率

Incidence of Endocrine and Exocrine Pancreatic Insufficiency after Minimally Invasive Parenchyma-Sparing Pancreatectomy.
PubMed 文献 · J Am Coll Surg · 2026-03-26

单中心回顾性分析2006至2024年因良性及低级别胰腺肿瘤行微创胰腺切除的184例患者,经倾向评分匹配比较微创保留实质胰腺切除(MI-PSP)与微创标准胰腺切除(MI-P)。MI-PSP组术后新发或加重糖尿病及胰腺外分泌功能不全(PEI)的发生率均低于MI-P组,多因素分析显示MI-P是二者独立的危险因素。

要点

  • MI-PSP组术后新发或加重糖尿病9例(9.8%),需胰岛素3例(3.3%),均低于MI-P组。
  • MI-PSP组PEI发生率为5.4%,显著低于MI-P组的22%(p=0.001)。
  • 多因素分析显示MI-P与术后糖尿病(HR 3.06)及PEI(OR 3.18)风险升高相关。

核心结论

  • 在良性及低级别胰腺肿瘤的外科治疗中,MI-PSP与术后代谢并发症(新发或加重糖尿病及PEI)发生率较低相关。
  • 多因素分析中,MI-P组发生新发或加重糖尿病的风险显著高于MI-PSP组(HR 3.06,p=0.006)。
  • 多因素分析中,MI-P组发生PEI的风险显著高于MI-PSP组(OR 3.18,p=0.037)。

研究设计与样本

  • 单中心回顾性分析,纳入2006至2024年因良性及低级别胰腺肿瘤行微创胰腺切除的患者,共184例。
  • 低级别肿瘤定义为转移风险低的局限性肿瘤。
  • 采用1:1倾向评分匹配,按年龄、性别、BMI、术前非胰岛素依赖型糖尿病及肿瘤大小比较MI-PSP与MI-P。
  • 采用多因素回归模型评估术后新发或加重糖尿病及PEI的风险。

主要发现

  • 两组90天内Clavien-Dindo≥3级并发症无显著差异(p=0.7)。
  • MI-P组21例(23%)发生新发或加重糖尿病,其中11例(12%)需胰岛素;MI-PSP组9例(9.8%),其中3例(3.3%)需胰岛素。
  • 新发或加重糖尿病的5年累积发病风险:MI-P组38.9%(95%CI 20.7至52.9),MI-PSP组26.7%(95%CI 7.5至42),p=0.008。
  • PEI发生率:MI-P组22%,MI-PSP组5.4%(p=0.001)。

临床怎么用

  • 对良性及低级别胰腺肿瘤,在技术可行时优先考虑保留胰腺实质的微创切除,以降低术后糖尿病和PEI风险。
  • 术后随访应关注血糖代谢及胰腺外分泌功能,尤其对行标准胰腺切除的患者。

局限性

  • 为单中心回顾性研究,样本量184例,可能存在选择偏倚与残留混杂。
  • 良性及低级别肿瘤定义与匹配变量有限,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimally invasive parenchyma-sparing pancreatectomy (MI-PSP) is being increasingly adopted for benign and low-grade pancreatic tumors. We sought to evaluate whether this approach is associated with reduced incidence of postoperative diabetes mellitus (DM) and pancreatic exocrine insufficiency (PEI). STUDY DESIGN: We conducted a retrospective single-institution analysis of patients undergoing minimally invasive pancreatectomy between 2006 and 2024 for benign and low-grade pancreatic tumors, defined as localized neoplasms with a low risk of metastases. Propensity score matching (1:1) was performed to compare MI-PSP and minimally invasive standard pancreatectomy (MI-P) based on age, sex, BMI, preoperative non-insulin-dependent DM, and tumor size. The risk of developing postoperative new-onset or worsening DM and PEI was assessed using a multivariable regression model. RESULTS: A total of 184 patients were included. No significant difference emerged between the 2 groups regarding postoperative complications (Clavien-Dindo grade 3 or higher) within 90 days (p = 0.7). Among patients undergoing MI-P, 21 (23%) developed new-onset or worsening diabetes, with 11 (12%) requiring insulin. In contrast, among patients undergoing MI-PSP, only 9 (9.8%) developed new-onset or worsening diabetes, with 3 (3.3%) needing insulin treatment. The 5-year cumulative incidence risk of developing new-onset or worsening diabetes was 38.9% (95% CI 20.7 to 52.9) in the MI-P group and 26.7% (95% CI 7.5 to 42) in the MI-PSP group (p = 0.008). Similarly, PEI developed in 22% of MI-P vs 5.4% of MI-PSP patients (p = 0.001). In the multivariable analysis, patients undergoing MI-P exhibited a significantly higher risk of developing new-onset or worsening diabetes (hazard ratio 3.06, p = 0.006) and PEI (odds ratio 3.18, p = 0.037) compared with those receiving MI-PSP. CONCLUSIONS: MI-PSP was associated with a lower incidence of postoperative metabolic complications in the management of benign and low-grade pancreatic tumors.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Solinas D, Dal Molin M, Campbell BA, et al. Incidence of Endocrine and Exocrine Pancreatic Insufficiency after Minimally Invasive Parenchyma-Sparing Pancreatectomy. J Am Coll Surg. 2026. PMID: 41532651. doi:10.1097/XCS.0000000000001758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。